Systems Level-based RNAi Screening by High Content Analysis Identifies UBR5 As a Regulator of Estrogen Receptor-α Protein Levels and Activity
Overview
Affiliations
Estrogen receptor-α (ERα) is a central transcription factor that regulates mammary gland physiology and a key driver in breast cancer. In the present study, we aimed to identify novel modulators of ERα-mediated transcriptional regulation via a custom-built siRNA library screen. This screen was directed against a variety of coregulators, transcription modifiers, signaling molecules and DNA damage response proteins. By utilizing a microscopy-based, multi-end point, estrogen responsive biosensor cell line platform, the primary screen identified a wide range of factors that altered ERα protein levels, chromatin remodeling and mRNA output. We then focused on UBR5, a ubiquitin ligase and known oncogene that modulates ERα protein levels and transcriptional output. Finally, we demonstrated that UBR5 also affects endogenous ERα target genes and E2-mediated cell proliferation in breast cancer cells. In conclusion, our multi-end point RNAi screen identified novel modulators of ERα levels and activity, and provided a robust systems level view of factors involved in mechanisms of nuclear receptor action and pathophysiology. Utilizing a high throughput RNAi screening approach we identified UBR5, a protein commonly amplified in breast cancer, as a novel regulator of ERα protein levels and transcriptional activity.
Duan C, Li Y, Zhi H, Tian Y, Huang Z, Chen S Acta Pharmacol Sin. 2024; 45(9):1793-1808.
PMID: 38740904 PMC: 11336169. DOI: 10.1038/s41401-024-01290-z.
UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.
Tsai J, Aguirre J, Li Y, Brown J, Focht V, Kater L Mol Cell. 2023; 83(15):2753-2767.e10.
PMID: 37478846 PMC: 11134608. DOI: 10.1016/j.molcel.2023.06.028.
CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics.
Tiwari P, Ko T, Dubey R, Chouhan M, Tsai L, Singh H Front Mol Biosci. 2023; 10:1214489.
PMID: 37469704 PMC: 10352522. DOI: 10.3389/fmolb.2023.1214489.
CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope.
Karn V, Sandhya S, Hsu W, Parashar D, Singh H, Jha N Cancer Cell Int. 2022; 22(1):234.
PMID: 35879772 PMC: 9316746. DOI: 10.1186/s12935-022-02654-3.
Wu B, Song M, Dong Q, Xiang G, Li J, Ma X Theranostics. 2022; 12(11):5086-5102.
PMID: 35836797 PMC: 9274738. DOI: 10.7150/thno.74989.